


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31198461</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1857-9655</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>May</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Open access Macedonian journal of medical sciences</Title>
                <ISOAbbreviation>Open Access Maced J Med Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>New Advances in Evaluation of Hearing in a Sample of Egyptian Children with β-Thalassemia Major.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1494-1498</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3889/oamjms.2019.316</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate hearing in β-thalassemia major patients on iron chelation therapy by using pure-tone audiometry (PTA) and distortion product otoacoustic emissions (DPOAE).</AbstractText>
                <AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">This cross-sectional, descriptive study was done on (48) diagnosed, 6-18 years old, β-thalassemia major patients who had received at least 3 years iron chelating agent deferoxamine (DFO). We performed PTA, DPOAE testing, and tympanometry for all participants. SPSS was used to analyse data. P &lt; 0.05 was accepted as statistically significant.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant difference was found between PTA and DPOAE testing in their capability to detect ototoxicity. PTA and DPOAE testing for the detection of ototoxicity in BTM and BTI, kappa values (κ) were found to be 0.516 and 0.459, respectively. The whole mean serum ferritin level was 2,251.3 ng/ml. The mean level was 1,603 ± 1,380 ng/ml in the patients with SNHL and 2,405 ± 1,908 ng/ml in the patients with normal hearing with the statistically significant difference among both groups (p = 0.015). The occurrence of ototoxicity was statistically significant with increasing age (p &lt; 0.001). There was no marked difference as regards gender (p = 0.72).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Hearing loss is prevailing in patients with β-thalassemia major on iron chelating agents. Therefore, regular hearing evaluations and periodic check-ups after the initiation of chelation therapy are mandatory.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alzaree</LastName>
                    <ForeName>Fatma A</ForeName>
                    <Initials>FA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Child Health, Medical Research Division, National Research Centre, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shehata</LastName>
                    <ForeName>Manal A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Child Health, Medical Research Division, National Research Centre, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Atti</LastName>
                    <ForeName>Mohamed Abdel</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Child Health, Medical Research Division, National Research Centre, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elzaree</LastName>
                    <ForeName>Gihan A</ForeName>
                    <Initials>GA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Audiology, Al-Azhar University, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El-Kassas</LastName>
                    <ForeName>Ghada M</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Child Health, Medical Research Division, National Research Centre, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Macedonia</Country>
            <MedlineTA>Open Access Maced J Med Sci</MedlineTA>
            <NlmUniqueID>101662294</NlmUniqueID>
            <ISSNLinking>1857-9655</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Egyptian Children</Keyword>
            <Keyword MajorTopicYN="N">Hearing loss</Keyword>
            <Keyword MajorTopicYN="N">Iron chelation therapy</Keyword>
            <Keyword MajorTopicYN="N">Ototoxicity</Keyword>
            <Keyword MajorTopicYN="N">β-Thalassemia major</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31198461</ArticleId>
            <ArticleId IdType="doi">10.3889/oamjms.2019.316</ArticleId>
            <ArticleId IdType="pii">OAMJMS-7-1494</ArticleId>
            <ArticleId IdType="pmc">PMC6542395</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

